OTCPK:LXGT.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lexington Biosciences, Inc. does not have significant operations. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Lexington Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LXGT.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

21.4%

LXGT.F

-3.8%

US Medical Equipment

-2.4%

US Market


1 Year Return

0%

LXGT.F

14.0%

US Medical Equipment

12.0%

US Market

Return vs Industry: LXGT.F underperformed the US Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: LXGT.F underperformed the US Market which returned 10.9% over the past year.


Shareholder returns

LXGT.FIndustryMarket
7 Day21.4%-3.8%-2.4%
30 Day-5.6%-3.7%-6.5%
90 Day-34.6%11.0%8.4%
1 Year0%0%15.0%14.0%14.5%12.0%
3 Year-97.2%-97.2%66.4%62.1%34.8%25.8%
5 Yearn/a134.4%116.6%82.1%61.6%

Price Volatility Vs. Market

How volatile is Lexington Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Lexington Biosciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lexington Biosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexington Biosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LXGT.F's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Lexington Biosciences regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Lexington Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lexington Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LXGT.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Lexington Biosciences's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Lexington Biosciences performed over the past 5 years?

41.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LXGT.F is currently unprofitable.

Growing Profit Margin: LXGT.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LXGT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.

Accelerating Growth: Unable to compare LXGT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LXGT.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: LXGT.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Lexington Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: LXGT.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LXGT.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LXGT.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LXGT.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LXGT.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LXGT.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.5% each year.


Next Steps

Dividend

What is Lexington Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LXGT.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LXGT.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LXGT.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LXGT.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LXGT.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average board tenure


CEO

Donald McInnes

0.42

Tenure

Mr. Donald Arthur McInnes serves as the Chief Executive Officer at Lexington Biosciences, Inc. since April 2020 and served as an Advisor until April 2020. Since 1993, Mr. McInnes has been the founder, pres ...


Board Members

NamePositionTenureCompensationOwnership
Jonathan Maltz
Chief Scientific Advisor3.17yrsno datano data
Douglas Janzen
Independent Board Chairmanno datano data0.53%
CA$ 1.7k
Gregory Robertson
Member of Medical Advisory Board3.17yrsno datano data
John Disher
Independent Director3.75yrsno data1.32%
CA$ 4.3k
James Wall
Member of Medical Advisory Board3.17yrsno datano data
Jeffrey Olgin
Member of Medical Advisory Board3.17yrsno datano data
Tamara Manuel
Director0.42yrno datano data

3.2yrs

Average Tenure

Experienced Board: LXGT.F's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lexington Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lexington Biosciences, Inc.
  • Ticker: LXGT.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$321.881k
  • Shares outstanding: 3.79m
  • Website: https://www.lexingtonbiosciences.com

Location

  • Lexington Biosciences, Inc.
  • 1055 West Hastings Street
  • Suite 1900
  • Vancouver
  • British Columbia
  • V6E 2E9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LXGT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2017

Biography

Lexington Biosciences, Inc. does not have significant operations. Previously, it was engaged in the development and commercialization of non-invasive diagnostic products for cardiovascular health. The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 06:52
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.